Uniqure Huntington’s, Veru, Aera, Gilead: Readout Publication
Need to keep on prime of the science and politics driving biotech at present? Enroll to get our biotech e-newsletter in your inbox.
Good morning. We’ve received large information on a gene remedy for Huntington’s illness, so let’s get straight to it.
Uniqure hails ‘groundbreaking’ ends in gene remedy trial in Huntington’s illness
An experimental gene remedy from Uniqure slowed the development of Huntington’s illness by 75% after three years — examine outcomes reported this morning which can be prone to help the primary approval of a genetic therapy for the uncommon neurodegenerative situation.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
